According to the Zhitong Finance App, Medi Weikang (02159) announced the results for the year ended December 31, 2023. Group revenue was RMB 331 million (same unit), up 2.45% year on year; loss attributable to shareholders was RMB 94.96 million, up 5.49% year on year; loss per share was 49.15 points.

The announcement stated that the company actively responds to trends, focuses on developing its main business, and strives to seize opportunities in the digital economy. The Group applies the latest artificial intelligence technology and web 3.0 digital technology to business innovation to inject new momentum into business growth. At the same time, we actively expand and upgrade digital pharmaceutical market services, achieve accurate digital services through data analysis, and improve the quality and efficiency of academic promotion.